Potentially disruptive technologies
We have three highly differentiated technologies focused on next generation anthracycline, immune/transcription modulators and metabolism/glycosylation inhibitors.
The Next Generation Anthracycline
Annamycin is a unique next-generation liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms that often defeat currently approved anthracyclines.
An Immune/Transcription Modulator
WP1066 is one of several Immune/Transcription Modulators, designed to stimulate the immune response to tumors by inhibiting the errant activity of Regulatory T-Cells while also inhibiting key oncogenic transcription factors, including p-STAT3, c-Myc and HIF-1α.
A Metabolism/Glycosylation Inhibitor
WP1122 is a prodrug of a well-known glucose decoy called 2-deoxy-D-glucose, or 2-DG, which enables increased cellular uptake, increased drug half-life and, importantly, an increased ability to cross the blood brain barrier, enabling greater uptake in the brain.